EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling

Yen-Lin Lai iD, Jin-Yuan Shih iD, Ching-Chow Chen iD

Molecular Oncology · 16.11.2026

DOI: 10.1002/1878-0261.70360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 16.11.2026. Verfasst von Yen-Lin Lai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to osimertinib remains a major challenge in EGFR‐mutant non‐small cell lung cancer (NSCLC). Using an osimertinib‐resistant (AR) cell model lacking the on‐target EGFR C797S mutation, we uncover sustained AKT phosphorylation under osimertinib treatment driven by insulin receptor (INSR) signaling. Notably, INSR–AKT activation is observed exclusively in AR cells, whereas parental H1975 cells fail to activate AKT even following INSR overexpression or exogenous insulin stimulation. Cholesterol depletion abolishes the INSR–AKT response in AR cells, indicating a lipid raft‐dependent mechanism. Consistently, INSR localizes within lipid rafts in AR but not in parental H1975 cells. Proteomic profiling reveals the enrichment of lipid raft‐associated proteins in AR cells. Among them, flotillin‐1 (FLOT1) is identified as a key raft scaffold mediating INSR–AKT signaling and osimertinib resistance through functional shRNA screening. Co‐immunoprecipitation and proximity ligation assay confirm a cholesterol‐dependent interaction between FLOT1 and INSR. Functionally, FLOT1 knockdown disrupts raft‐associated INSR localization, attenuates AKT activation, and reduces the IC 50 of osimertinib in AR cells. Collectively, these findings demonstrate that lipid raft‐dependent INSR–AKT signaling contributes to osimertinib resistance in NSCLC.

Schlagwörter

Stichwörter der Autor:innen

NSCLCcholesterolinsulin receptorlipid raftosimertinibresistance

Autor:innen und Institutionen

  • Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

ORCID-Profile: Yen-Lin Lai, Jin-Yuan Shih, Ching-Chow Chen

Zitieren

APA

Lai, Y. L., Shih, J. Y., & Chen, C. C. (2026). Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling. Molecular Oncology. https://doi.org/10.1002/1878-0261.70360

Vancouver

Lai YL, Shih JY, Chen CC. Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling. Molecular Oncology. 2026. doi:10.1002/1878-0261.70360

BibTeX
@article{Lai2026,
  author = {Lai, Yen-Lin and Shih, Jin-Yuan and Chen, Ching-Chow},
  title = {Osimertinib resistance in non‐small cell lung cancer is mediated by sustained AKT activation through lipid raft‐dependent insulin signaling},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70360}
}
Kostenlos starten →